Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
暂无分享,去创建一个
J. Emberson | H. Halls | P. Kearney | C. Patrono | C. Baigent | J. Godwin
[1] M. Brochier. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. , 1993, European heart journal.
[2] M. Lavezzari,et al. Indobufen in the Prevention of Thromboembolic Complications in Patients With Heart Disease A Randomized, Placebo‐Controlled, Double‐Blind Study , 1993, Circulation.
[3] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[4] R Day,et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.
[5] S A Rich,et al. The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.
[6] Karen A Robinson,et al. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. , 2002, International journal of epidemiology.
[7] C. Patrono,et al. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. , 2003, Arthritis and rheumatism.
[8] P. Duke,et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. , 2003, The Journal of thoracic and cardiovascular surgery.
[9] T. Schnitzer,et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial , 2004, The Lancet.
[10] C. Lines,et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.
[11] Marc A Pfeffer,et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.
[12] Colin Baigent,et al. Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.
[13] B. Psaty,et al. Parecoxib, valdecoxib, and cardiovascular risk. , 2005, Circulation.
[14] Andreas Hoeft,et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.
[15] Review: selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs , 2006, Evidence-based medicine.